Anti-KCNH2/ ERG-1/ ERG1 monoclonal antibody

Anti-KCNH2/ ERG-1/ ERG1 antibody for FACS & in-vivo assay

Target products collectionGo to KCNH2/KCNH2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T20251-Ab-1/ GM-Tg-hg-T20251-Ab-2Anti-Human KCNH2 monoclonal antibodyHuman
GM-Tg-rg-T20251-Ab-1/ GM-Tg-rg-T20251-Ab-2Anti-Rat KCNH2 monoclonal antibodyRat
GM-Tg-mg-T20251-Ab-1/ GM-Tg-mg-T20251-Ab-2Anti-Mouse KCNH2 monoclonal antibodyMouse
GM-Tg-cynog-T20251-Ab-1/ GM-Tg-cynog-T20251-Ab-2Anti-Cynomolgus/ Rhesus macaque KCNH2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T20251-Ab-1/ GM-Tg-felg-T20251-Ab-2Anti-Feline KCNH2 monoclonal antibodyFeline
GM-Tg-cang-T20251-Ab-1/ GM-Tg-cang-T20251-Ab-2Anti-Canine KCNH2 monoclonal antibodyCanine
GM-Tg-bovg-T20251-Ab-1/ GM-Tg-bovg-T20251-Ab-2Anti-Bovine KCNH2 monoclonal antibodyBovine
GM-Tg-equg-T20251-Ab-1/ GM-Tg-equg-T20251-Ab-2Anti-Equine KCNH2 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T20251-Ab-1/ GM-Tg-hg-T20251-Ab-2; GM-Tg-rg-T20251-Ab-1/ GM-Tg-rg-T20251-Ab-2;
GM-Tg-mg-T20251-Ab-1/ GM-Tg-mg-T20251-Ab-2; GM-Tg-cynog-T20251-Ab-1/ GM-Tg-cynog-T20251-Ab-2;
GM-Tg-felg-T20251-Ab-1/ GM-Tg-felg-T20251-Ab-2; GM-Tg-cang-T20251-Ab-1/ GM-Tg-cang-T20251-Ab-2;
GM-Tg-bovg-T20251-Ab-1/ GM-Tg-bovg-T20251-Ab-2; GM-Tg-equg-T20251-Ab-1/ GM-Tg-equg-T20251-Ab-2
Products NameAnti-KCNH2 monoclonal antibody
Formatmab
Target NameKCNH2
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-KCNH2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species KCNH2/ ERG-1/ ERG1 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-T20251
    Target NameKCNH2
    Gene ID3757,16511,117018,714174,403761,101081621,539971,100064000
    Gene Symbol and Synonymscerg,derg,erg,ERG-1,ERG1,H-ERG,HERG,HERG1,KCNH2,Kv11.1,LQT,LQT2,M-erg,Merg1,merg1a,merg1b,SQT1
    Uniprot AccessionQ12809,O08962,Q9TSZ3
    Uniprot Entry NameKCNH2_HUMAN,KCNH2_RAT,KCNH2_CANLF
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target
    DiseaseN/A
    Gene EnsemblENSG00000055118
    Target ClassificationIon Channel

    The target: KCNH2, gene name: KCNH2, also named as ERG-1, ERG1, H-ERG, HERG, HERG1, Kv11.1, LQT2, SQT1. This gene encodes a component of a voltage-activated potassium channel found in cardiac muscle, nerve cells, and microglia. Four copies of this protein interact with one copy of the KCNE2 protein to form a functional potassium channel. Mutations in this gene can cause long QT syndrome type 2 (LQT2). Transcript variants encoding distinct isoforms have been identified. [provided by RefSeq, May 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.